Navigation Links
BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
Date:12/5/2008

enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
2. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
3. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
4. BioCryst to Present at the JMP Healthcare Focus Conference
5. BioCryst to Present at UBS 2008 Global Life Sciences Conference
6. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
7. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
8. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
9. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
10. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
11. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... the University of Leicester has furthered our understanding ... to create new materials using nanosized ,building blocks,. ... the prestigious academic journal Physical Review Letters ... in rich detail the structure and internal atomic ... molecule and a single helium atom. , The ...
(Date:7/25/2014)... Lawrence Livermore scientists Charles Westbrook and William ... " The World's Most Influential Scientific Minds ." , ... who were identified by analyzing citation data over the ... highest-impact work (2002-2012 and 2012-2013). The two were selected ... . , "This recognition is a great honor for ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... at American Society of Pharmacognosy, EMERYVILLE, Calif., ... will present seminal information on a new drug ... 7th Annual Oxford International,Conference on the Science of ... April 12-16, 2008. Scott Baggett, Ph.D., a member ...
... April 14 Codexis, Inc. announced,today that it has ... U.S.,Securities and Exchange Commission ("SEC") relating to the proposed ... of the Codexis,registration statement on Form S-1 can be ... shares being offered and the price,range for the offering ...
... and reduced cost for ... pharmaceutical manufacturers, NEW YORK, ... agreement with Chiral Quest, Inc., a manufacturer and,developer of chiral ... chiral products to the pharmaceutical industry., Effective immediately, Sumitomo ...
Cached Biology Technology:Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 2Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest 2
(Date:7/24/2014)... use of native animal species for food or commercial ... significant factor in the decline of many species of ... indicates that more than half of the species being ... hornbills., "By surveying not only the meat made available ... inside the forest by hunters and brought to villages ...
(Date:7/24/2014)... has identified two factors that characterize sustainable university ... of highly qualified physics teachers. Specifically, one or ... teacher education in combination with institutional motivation and ... Science, Technology, Engineering and Math (STEM) teacher shortages ... points the way for institutions seeking to increase ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2
... known for years that damaged DNA can lead to human ... it--has remained less clear. , Now, computational chemists at ... that when a proton is knocked off one of the ... damage begins that causes "lesions" in the DNA. These lesions, ...
... the IODP Arctic Coring Expedition (ACEX) is making news with ... of Nature, an article by several of the expedition scientists ... warm, unusually wet, and ice-free up to the time the ... Earth's atmosphere ?a period calculated to have occurred 55 million ...
... the more advanced species stopped making a protein that ... the HIV-1 virus from entering and infecting blood cells. ... designed to prevent infections. But a research team led ... of Biomedical Sciences has demonstrated that over 100 days ...
Cached Biology News:'Pinball protons' created by ultraviolet rays and other causes can lead to DNA damage 2Arctic coring expedition continues to yield new clues 2Defense peptide found in primates may block some human HIV transmissions 2Defense peptide found in primates may block some human HIV transmissions 3